Long non-coding RNA CRALA is associated with poor response to chemotherapy in primary breast cancer
Autor: | Shunying Li, Baoxiao Wang, Yudong Li, Hongna Lai, Yichao Fang, Yujie Liu, Qiuting You, Qian Li |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology CA15-3 medicine.medical_specialty Chemotherapy Gene knockdown business.industry medicine.medical_treatment Cancer General Medicine medicine.disease Long non-coding RNA 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Breast cancer 030220 oncology & carcinogenesis Internal medicine medicine Biomarker (medicine) Gene silencing business |
Zdroj: | Thoracic Cancer. 8:582-591 |
ISSN: | 1759-7706 |
Popis: | Background Breast cancer is the most commonly diagnosed cancer in women, and has become the second leading cause of cancer death among women worldwide. Chemoresistance has become an important problem in breast cancer clinics. The identification of new mechanisms affecting chemosensitivity is of great clinical value for the treatment of breast cancer. Methods The expression levels of chemoresistance-associated long non-coding RNA (CRALA), a newly discovered long non-coding RNA, were measured by quantitative real time-PCR in 79 pre-treatment biopsied primary breast cancer samples. Small interfering RNAs were used to knockdown CRALA expression. The effect of CRALA on chemosensitivity was evaluated using cell growth assay. Results Non-responding tumors (poor response to chemotherapy, 32 samples) had fourfold higher CRALA expression than responding tumors (good response to chemotherapy, 47 samples). CRALA is upregulated in chemoresistant breast cancer cell lines compared to their parental lines. Silencing of CRALA in chemoresistant breast cancer cells resensitizes the cells to chemotherapy in vitro. Furthermore, univariate and multivariate analysis showed that higher CRALA expression was significantly associated with poor prognosis in 144 breast cancer patients. Conclusion The study findings indicate that CRALA expression may be an important biomarker for predicting the clinical response to chemotherapy and prognosis in breast cancer patients. It is possible to target CRALA to reverse chemoresistance in breast cancer patients. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |